Laurent Pharmaceuticals Wins FDA and Health Canada Clearance for Phase 2 Clinical Study of LAU-7b

The FDA and Health Canada have cleared Laurent Pharmaceuticals to launch a Phase 2 study for the treatment of cystic fibrosis in adults.

LAU-7b is a once-a-day oral therapy with potential to treat chronic pulmonary inflammation that leads to irreversible lung damage in patients with cystic fibrosis.

The study will enroll about 136 adults with CF for a 6-month treatment.

The trial is planned to start later this year in the U.S. and Canada.